Compare GERN & COUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | COUR |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | 258 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.3M | 932.9M |
| IPO Year | N/A | 2021 |
| Metric | GERN | COUR |
|---|---|---|
| Price | $1.26 | $5.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $2.17 | ★ $10.53 |
| AVG Volume (30 Days) | ★ 13.9M | 6.0M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $757,500,000.00 |
| Revenue This Year | $26.91 | $9.43 |
| Revenue Next Year | $43.75 | $6.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.04 |
| 52 Week Low | $1.04 | $5.00 |
| 52 Week High | $2.01 | $13.56 |
| Indicator | GERN | COUR |
|---|---|---|
| Relative Strength Index (RSI) | 34.40 | 47.18 |
| Support Level | $1.22 | $5.09 |
| Resistance Level | $1.29 | $6.41 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 21.15 | 52.16 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.